Saman Kojouri
Press TV, Tehran
The head of Razi Vaccine and Serum Research Institute says the Razi Cov-Pars vaccine will be an excellent option as it is the first injectable-inhaled COVID-19 vaccine of recombinant protein.
Dr Ali Eshaqi, speaking at a press conference said the vaccine produced by the Razi Institute of Iran does not contain any elements other than the ingredients required for the vaccine.
The press conference came only one day after Iran unveiled its second domestically-made vaccine titled Razi Cov-Pars.
Razi COV-Pars is administered in three stages; two intramuscular shots 21 days apart and an intranasal administration 30 days after the second jab. Developers say not only does this protect the recipient from the virus, but it prevents them from transmitting the virus to others. Those who receive the COV-Pars vaccine will not need a mask anymore.
Its domestic rival, Iran’s first homegrown vaccine Coviran, is ahead in schedule and will start the second phase of the human trial next month. At the same time, Iran has imported the first batch of Russia’s Sputnik V and will kick-start its mass vaccination this week.
The first phase of the human trial for COV-Pars will start next week on 130 volunteers. Developers say the entire human trial stage will take some five months.